Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment

Carol Ward, James Meehan, Mark Gray, Ian H. Kunkler, Simon P. Langdon, Alan Murray, David Argyle

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The immense costs in both financial terms and preclinical research effort that occur in the development of anticancer drugs are unfortunately not matched by a substantial increase in improved clinical therapies due to the high rate of failure during clinical trials. This may be due to issues with toxicity or lack of clinical effectiveness when the drug is evaluated in patients. Currently, much cancer research is driven by the need to develop therapies that can exploit cancer cell adaptations to conditions in the tumor microenvironment such as acidosis and hypoxia, the requirement for more-specific, targeted treatments, or the exploitation of ‘precision medicine’ that can target known genomic changes in patient DNA. The high attrition rate for novel anticancer therapies suggests that the preclinical methods used in screening anticancer drugs need improvement. This chapter considers the advantages and disadvantages of 3D organotypic models in both cancer research and cancer drug screening, particularly in the areas of targeted drugs and the exploitation of genomic changes that can be used for therapeutic advantage in precision medicine.

Original languageEnglish
Title of host publicationThree Dimensional Human Organotypic Models for Biomedical Research
PublisherSpringer
Pages225-246
Number of pages22
ISBN (Electronic)9783030624521
ISBN (Print)9783030624514
DOIs
Publication statusPublished - 12 Mar 2019

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume430
ISSN (Print)0070-217X
ISSN (Electronic)2196-9965

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment'. Together they form a unique fingerprint.

Cite this